Analysis of change in MADRS score ( LOCF ) by baseline symptom severity ( MADRS score of 12 , 14 , 16 , 18 ) showed significantly greater improvement for lurasidone-treated patients across all severity groups ; effect sizes ranged from 0.25 to 0.34 .